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ABSTRACT
We have generated an optimized inducible recom-
bination system for conditional gene targeting
based on a Cre recombinase±steroid receptor
fusion. This con®guration allows ef®cient Cre-medi-
ated recombination in most organs of the mouse
upon induction, without detectable background
activity. An ES cell line, was established that carries
the inducible recombinase and a loxP-¯anked lacZ
reporter gene. Out of this line, completely ES cell-
derived mice were ef®ciently produced through tet-
raploid blastocyst complementation, without the
requirement of mouse breeding. Our ®ndings pro-
vide a new concept allowing the generation of indu-
cible mouse mutants within 6 months, as compared
to 14 months using the current protocol.
INTRODUCTION
Conditional gene targeting has become increasingly used in
reverse mouse genetics, as it facilitates setting the site and
time of gene inactivation in the body (1±3). This is achieved
by the expression of the site-speci®c DNA recombinase Cre in
conjunction with the target gene containing two Cre recog-
nition sites (loxP). In the conditional mouse mutant, inactiva-
tion of the target gene is restricted in a spatial and/or temporal
manner, depending on the expression pattern of the recom-
binase. Since the initial demonstration of this technology in
1994 (4), an increasing number of conditional knockout
experiments have been published, most of which employed
tissue-speci®c promoters to control Cre expression. Spatially
regulated gene inactivation has proven to be powerful in
dissecting the role of different cell types in a physiological
process, as demonstrated for example by studies concerning
the role of insulin receptor signaling in glucose homeostasis
(5). The method of choice for precise gene function analyses
in adult mice, however, is the temporal control of gene
inactivation as it can prevent impaired embryonic develop-
ment until the time of induction. In particular, inducible gene
targeting in all organs would be a useful tool if the major site
of gene action is not precisely de®ned. Optimally, such a
system should permit a tight control of gene inactivation,
ef®cient recombination in every single cell of the body upon
induction, and the opportunity to produce suf®cient numbers
of inducible mouse mutants within a short time.
The major drawback of the current strategy is the long time
frame required for the derivation of a conditional mouse
mutant. Since two copies of the loxP-¯anked allele must be
combined with the recombinase transgene, at least three
breeding steps (3 months each) are required to obtain a
reasonable number of mice with the desired genotype (see
Fig. 5A). While the ®rst conditional mouse mutants can be
expected within 14 months, additional time for breeding is
usually needed to obtain suf®cient numbers of mice for
phenotypic analysis. To date, only a few mouse strains
permitting ubiquitously inducible gene targeting are available,
all of which suffer from incomplete recombination upon
induction or background activity in the absence of inducer
(6±10). Recently, a mouse strain has been generated by the
insertion of a tamoxifen-inducible CreER fusion protein gene
into the ubiquitously expressed Rosa26 gene (11). While this
strain represented the most ef®cient tool for ubiquitously
inducible gene targeting so far, a low af®nity ER domain was
used that requires high doses of the inducer 4-hydroxytamox-
ifen to achieve the maximal rate of recombination. Therefore,
the side effects of the inducer may interfere with the
phenotypic outcome of target gene inactivation. Taken
together, there is a need for improved methods which both
enable ef®cient gene knockout in all organs at non-toxic
concentrations of the inducer and which accelerate the
production of inducible mouse mutants.
In this paper we describe a novel approach for the rapid
generation of inducible mouse mutants, which overcomes the
drawbacks of the current technology. The approach is based
on a ubiquitously expressed, high af®nity CreER fusion
protein that allows the ef®cient inducible inactivation of a
loxP-¯anked target gene in most organs. In addition, we
demonstrate that hybrid ES cells tolerate at least three
consecutive gene targeting cycles including selection with
the antibiotics G418 and hygromycin B without affecting the
potency to complement tetraploid blastocysts. Our ®ndings
provide a new concept allowing the rapid production of ES
cell-derived, inducible knockout mice.
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MATERIALS AND METHODS
Construction of vectors
CreERT2. The Cre gene was ampli®ed by PCR (Expand High
Fidelity PCR system; Clontech) from PGKCrebpA using the
oligos PR-A (TAACTAGCGGCCGCGTCGACCATGTCC-
AATTTACTGACCGTACAC) and creER5 (TCTCATGTCT-
CCAGCAGAATCGCCATCTTCCAGCAGGCG). In parallel
the ER domain was ampli®ed from the CreED2 vector (12)
using the oligos creER4 (CTGGAAGATGGCGATTCTGC-
TGGAGACATGAGAGCTGCC) and creER1 (TAGTTAG-
CGGCCGCTCAGACTGTGGCAGGGAAACCCTC). Both
PCR products were used as overlapping templates in a PCR
with the primers PR-A and creER1. The resulting 2 kb product
was digested with NotI and inserted into the NotI site of pBS.
Site-directed mutagenesis (Stratagene) was applied to intro-
duce a G400V mutation using primers ER-G400Vs
(CATGGAGCACCCAGTGAAGCTACTGTTTG) and ER-
G400Vas (CAAACAGTAGCTTCACTGGGTGCTCCATG).
For the introduction of two amino acid changes, M543A/
L544A, the primers ER AA2¢ s EagI (ATGACCTGCTG-
CTGGAGGCGGCCGACGCCCACCGCCTAC) and ER AA2
as EagI (GTAGGCGGTGGGCGTCGGCCGCCTCCAGCA-
GCAGGTCAT) were used in a site-directed mutagenesis. The
creERT2 was inserted into an expression vector containing a
CMV promoter, an intron and a polyadenylation signal
resulting in the vector CMV-CreER.
Rosa targeting vector. A 129 SV/EV-BAC library (Incyte
Genomics) was screened with a probe against exon 2 of
the Rosa26 locus [ampli®ed from mouse genomic DNA
using Rscreen1s (GACAGGACAGTGCTTGTTTAAGG) and
Rscreen1as (TGACTACACAATATTGCTCGCAC)]. Out of
the identi®ed BAC clone an 11 kb EcoRV subfragment was
inserted into the HindII site of pBS. Two fragments (a 1 kb
SacII±XbaI and a 4 kb XbaI fragment) were used as homology
arms and inserted into a vector consisting of a FRT-¯anked
neomycin resistance gene (unpublished) and a splice acceptor
site from adenovirus (13).
CreERT2 knock-in vector. The CreERT2 coding sequence and a
polyadenylation site was inserted into the Rosa-targeting
vector.
Rosa(lacZ reporter) knock-in vector. The neo gene of the
Rosa-targeting vector was deleted through transformation of
FLP-expressing bacteria (14). In the resulting vector a cassette
containing a loxP-¯anked PGK-hygro-pA followed by lacZ
was inserted.
ect2 Targeting vector. The vector was generated by insertion
of PCR fragments (with attached restriction sites) ampli®ed
from BAC DNA (129SVJ) into a vector consisting of a FRT-
¯anked neomycin resistance gene ¯anked by two loxP sites
(G. Kauselmann, unpublished results). The 989 bp PCR
fragment of the 5¢ targeting arm was inserted with NotI/SgfI 5¢
of the loxP sites and the 4023 bp PCR fragment of the 3¢ arm
with XhoI/PmeI 3¢ of the loxP sites. The 428 bp PCR fragment
of exon 6 and the ¯anking intronic region were inserted with
AscI/FseI between the loxP sites.
Cell culture
Culture and targeted mutagenesis of ES cells were carried out
as previously described (15) with ES cell lines derived from
both inbred and F1 embryos.
Generation of ect2¯ox ES cells. The C57BL/6 cell line Bruce4
was electroporated with the described targeting vector, and out
of 480 clones 3 homologous recombined clones were detected.
Mice
All mice were kept in the animal facility at Artemis
Pharmaceuticals GmbH in microisolator cages (Tecniplast
Sealsave). B6D2F1 mice for the generation of tetraploid
blastocysts were obtained from Janvier. The polb¯ox/
rosa(CreERT2) and ect2¯ox/rosa(CreERT2) mice were gener-
ated by breeding of rosa(CreERT2) ES mice with bT14 (4) and
ect2¯ox females (unpublished), respectively.
Production of ES mice by tetraploid embryo
complementation
The production of mice by tetraploid embryo complementa-
tion was essentially performed as described (16).
Ligand administration
An aliquot of 100 mg tamoxifen-free base (T5648; Sigma) was
suspended in 100 ml ethanol and dissolved in 1 ml sun¯ower
oil (Sigma). This 10 mg/100 ml tamoxifen solution was
sonicated for 1±2 min and then stored at ±20°C. For p.o.
administration the solution was thawed at 55°C and admin-
istrated to 4±8-week-old mice by a feeding needle (18061-
20FST; Fine Science Tools GmbH).
Western blot analysis
Western blot analysis was performed using SDS±PAGE
(NuPAGE; Invitrogen) and the Breeze Immunodetection
System (Invitrogen) according to the manufacturer's proto-
cols. Immunodetection was done using HC-20 against ER,
PRB-106C against cre, I-19 against actin and rabbit polyclonal
IgG antibodies (Santa Cruz Biotechnology Inc.).
RESULTS
Design of F1 ES cells carrying an inducible Cre
transgene
To derive an optimized system for inducible gene targeting in
mice, we generated a fusion protein consisting of Cre
recombinase and the mutated ligand-binding domain of the
estrogen receptor ERT2 (17). The ERT2 domain is composed of
amino acids 282±595 of the human estrogen receptor and
carries three mutations (G400V/M543A/L544A) that confer a
103 enhanced sensitivity to the synthetic ligand 4-hydroxy-
tamoxifen in mice as compared to the previously used ERT
(G521R) domain (18). The CreERT2 coding region was
inserted into the ubiquitously expressed Rosa26 locus through
homologous recombination to obtain a con®guration that
allows the inducible inactivation of genes in all organs (Fig. 1).
The Rosa26 targeting vector containing the CreERT2 gene is
depicted in Figure 1A. We used the hybrid ES cell lines V6.5
[(C57BL/6 3 129S4Sv/Jae) F1] and ART4.12 [(C57BL/6 3
129S6/SvEvTac) F1] for homologous recombination, since
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these lines are capable of producing completely ES cell-
derived mice (ES mice) through tetraploid blastocyst
complementation with high ef®ciency (16). Independent
recombinant ES cell clones were obtained at a frequency of
2% as veri®ed by Southern blot analysis (Fig. 1B). Deletion of
the neo gene did not affect the level of CreERT2 expression as
determined by western blot analysis (Fig. 1D). A loxP-¯anked
hygromycin resistance gene was introduced into the second
allele of Rosa26 (Fig. 1A and C) to provide a similar test
substrate for Cre as the widely used Rosa26 reporter (19,20).
In ES cells carrying both the rosa(CreERT2) and the rosa(lacZ
reporter) alleles, complete recombination of the loxP-¯anked
segment was achieved upon treatment with 500 nM 4-
hydroxytamoxifen for 4.5 days (Fig. 1E). Half-maximal
activation of CreERT2 occurred at a concentration of 10 nM
4-hydroxytamoxifen (Fig. 1F) as compared to 100 nM for the
CreERT fusion protein (12).
Generation of ES cell-derived mice
The three types of recombinant and wild-type V6.5 and
ART4.12 ES cells were injected into tetraploid blastocysts and
ES mice were obtained upon transfer of these blastocysts into
pseudopregnant females. The proportion of transferred
blastocysts that further developed into live born pups was in
Figure 1. Generation of targeted ES cells. (A) Scheme of the gene targeting strategy. Both constructs were sequentially inserted into the Rosa26 locus by
homologous recombination as depicted. E, EcoRV; X, XbaI; Bg, BglI. (B) Southern blot analysis of genomic DNA from ES cells containing the targeted
insertion of CreERT2 before and after FLP-mediated deletion of the neomycin resistance gene. The DNA of ES cells was digested with BglI and hybridized
with probe 2. The sizes of the wild-type, targeted and Dneo alleles are 6.6, 7.6 and 9.0 kb, respectively. (C) Southern blot analysis of genomic DNA extracted
from double-targeted ES cells carrying the rosa(CreERT2) and rosa(lacZ reporter) alleles. Homologous recombination at the Rosa26 locus is detectable using
EcoRV-digested genomic DNA and probe 1, resulting in an 11.7 kb band for the wild-type and a 2.5 kb band for the targeted allele. (D) Western blot analysis
of CreERT2 expression in targeted ES cells before and after neo deletion. The western blot was probed with a Cre antiserum as described in Materials and
Methods. (E) Southern blot analysis of inducible recombination of the rosa(lacZ reporter) allele. Cells were treated for 4.5 days with 500 nM
4-hydroxytamoxifen (4-OHT). Southern blot analysis of EcoRV-digested DNA was performed using the rosa26-speci®c probe 1 depicted in (A). (F) Titration
of 4-OHT inducible recombination. Cells were treated for 3 days with increasing concentrations of 4-OHT as indicated. Southern blot analysis of
EcoRV-digested DNA was performed using the rosa26-speci®c probe 1.
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the range 8±17% and did not signi®cantly decrease when ES
cells were used that had undergone up to three sequential
rounds of transfection (Fig. 2A). In contrast, the production of
ES mice using inbred ES cells was inef®cient (0.2%),
con®rming the `hybrid vigor' effect described in Eggan et al.
(16) (Fig. 2A). Southern blot analysis of genomic DNA using a
Rosa26-speci®c probe showed that the V6.5/CreER/¯ox ES
mice were indeed solely derived from the recombinant ES
cells and did not contain any detectable tetraploid cells from
the injected blastocysts (Fig. 2B). These results demonstrate
that mice can be produced by tetraploid blastocyst comple-
mentation using cells that have undergone three consecutive
rounds of transfection, including two drug selection cycles.
Ubiquitously inducible gene targeting in mice
For the induction of CreERT2 in mice, we applied 1±5 mg
tamoxifen orally for 5 days in the following experiments. We
preferred to use this protocol, as the LD50 of tamoxifen in mice
is 15-fold higher via the oral route than by i.p. injection
(200 mg versus 5 g/kg) (21). It has been recently demonstrated
that the oral application of tamoxifen is as ef®cient as i.p.
injection of 4-hydroxytamoxifen for the activation of CreER
(22). Rosa(CreERT2/lacZ reporter) mice were fed with daily 5
mg tamoxifen for 5 days and recombination of the lacZ
reporter was analyzed 3 days after the last administration.
Southern analysis of genomic DNA from different organs
showed up to 50% recombination, without detectable back-
ground activity in untreated animals (Fig. 3A). This is a
signi®cantly higher degree of inducible recombination as
compared to the results obtained with the Rosa26-CreERT
strain (11), indicating that the ERT2 domain is indeed more
sensitive to 4-hydroxytamoxifen. Upon recombination, the
lacZ gene turned out to be inserted non-functionally, presum-
ably due to a second start codon upstream of the coding region.
Since the Rosa26 locus has a limited accessibility for Cre
(11), we were interested to test the rosa(CreERT2) con®gur-
ation in the context of other loxP-¯anked loci. As the second
substrate, we used the loxP-¯anked DNA polymerase b gene
segment (polb¯ox) (4). This allele had been used to characterize
a number of tissue-speci®c (4,12,23±26) as well as inducible
Cre strains (6,12), and shows an intermediate accessibility for
Cre (F. Schwenk and J. Seibler, unpublished observations).
The polb¯ox/rosa(CreERT2) mice were fed with 5 mg
tamoxifen/day for 5 days and analyzed 3 days later.
Southern blot analysis revealed that the loxP-¯anked poly-
merase b gene segment was excised in more than 90% of cells
in all organs except brain, whereas no background recombin-
ation was detected in untreated mice (Fig. 3B). As a third
substrate, we used a 2.5 kb loxP-¯anked segment of the ect2
gene. Again, up to 100% recombination in most tissues was
achieved upon tamoxifen treatment of ect2¯ox/rosa(CreERT2)
mice, without detectable background recombination in unin-
duced controls (Fig. 3C). A similar degree of recombination
was achieved when a shorter (0.5 kb) loxP-¯anked segment in
the same position of the ect2 gene was used (Fig. 3D). `Low
dose application' of 5 3 1 mg tamoxifen was suf®cient to
achieve complete recombination of the ect2¯ox allele in most
organs, further demonstrating the improved sensitivity of the
ERT2 domain in vivo.
To investigate whether the low recombination ef®ciency in
brain was due to low CreERT2 expression we performed
western analysis using antibodies speci®c for the human
Figure 2. Production ef®ciency of completely ES cell-derived mice. (A) ES cells with the indicated genotype were injected into tetraploid blastocysts. The
percentages of blastocysts that developed into live born ES pups are depicted. (B) Southern blot analysis of DNA extracted from liver of ES mice (lanes 2±9).
Genomic tail DNA from a wild-type ES mouse is used as a control (lane 1). DNA was digested with EcoRV and probed with the Rosa26-speci®c probe 1 as
depicted in Figure 1A.
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estrogen receptor. The 74 kDa band corresponding to the
CreERT2 fusion protein was detectable in all organs including
brain, with the highest levels in thymus, small intestine and
testis (Fig. 4). The limited degree of recombination in brain
may thus re¯ect a lower local concentration of 4-hydroxy-
tamoxifen rather than a reduced expression level of CreERT2.
DISCUSSION
We describe an optimized system that allows ubiquitously
inducible gene targeting in mice. This system is based on a
fusion protein consisting of Cre recombinase and a mutated
ligand-binding domain of the estrogen receptor that is
Figure 3. Inducible recombination in mice. Mice carrying different loxP-¯anked alleles were fed daily with 5 mg tamoxifen (A±D) or 1 mg tamoxifen (E) for
5 days. Cre-mediated deletion of the loxP-¯anked region was detected by Southern analysis 3 days after the treatment. (A) Rosa(CreERT2/lacZ reporter) mice.
Genomic DNA from various organs was digested with EcoRV and hybridized with a lacZ-speci®c probe. The percentages of deletion of the loxP-¯anked
allele, as quanti®ed with a Bio-Imaging Analyzer, are indicated. (B) polb¯ox/rosa(CreERT2) mice. Cre-mediated excision of the 1.5 kb loxP-¯anked region was
detected by Southern analysis. Genomic DNA from various organs was digested with BamHI and hybridized with a probe speci®c for the polymerase b gene
(4). (C) ect2¯ox/rosa(CreERT2) mice. The loxP sites are 2.5 kb apart from each other ¯anking a FRT-¯anked neomycin selection marker and exon 6 of the
ect2 gene (described in Materials and Methods). Genomic DNA was digested with HpaI and hybridized with an ect2-speci®c probe hybridizing upstream of
the loxP-¯anked region. (D) ect2¯oxDneo/rosa(CreERT2) mice. The ect2¯oxDneo allele was generated through FLP-mediated deletion of the neomycin selection
marker from the ect2¯ox allele resulting in a loxP-¯anked region of 0.5 kb containing exon 6 of the ect2 gene (described in Materials and Methods). Genomic
DNA was digested with HpaI and hybridized with an ect2-speci®c probe. (E) ect2¯ox/rosa(CreERT2) mice treated with 1 mg tamoxifen for 5 days. Genomic
DNA was digested with HpaI and hybridized with an ect2-speci®c probe hybridizing upstream of the loxP-¯anked region. Li, liver; Sp, spleen; Ki, kidney;
He, heart; Lu, lung; Th, thymus; Mu, muscle; Si, small intestine; Br, brain; Te, testis; Co, colon.
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expressed under the control of the ubiquitously active Rosa26
promoter (19). In contrast to the Rosa26-CreERT mouse strain
published by Vooijs et al. (11), we used the ERT2 domain that
responds at an ~10-fold lower dose of the synthetic inducer 4-
hydroxytamoxifen as compared to the ERT domain (17,18). In
mice, the rosa(CreERT2) con®guration achieved nearly com-
plete inducible excision of multiple loxP-¯anked gene
segments in all organs except brain, without background
recombination in the absence of inducer (Fig. 3). Thus, our
system permits the tight temporal control of ubiquitous gene
Figure 4. Western blot analysis of CreERT2 expression in ES mice. Proteins were extracted from rosa(CreERT2) targeted ES mice and analyzed as described
in Materials and Methods. Protein extracts from wild-type and rosa(CreERT2) targeted ES cells are used as controls. The positions of bands representing
CreERT2 and actin are indicated. Li, liver; SP, spleen; Ki, kidney; He, heart; Lu, lung; Th, thymus; Mu, muscle; Si, small intestine; Br, brain; Fa, fat tissue;
Te, testis.
Figure 5. The generation of inducible mouse mutants via the current protocol and via tetraploid blastocyst complementation. (A) The current protocol in-
cludes the generation of targeted ES cells, the FLP-mediated deletion of the neo gene, the production of chimeric mice, the breeding for germline transmission
and another two breeding steps to combine two copies of the loxP-¯anked allele with the recombinase transgene. Following this scheme, the generation of
conditional mouse mutants usually takes 14 months. Chimeras can be directly bred to Cre transgenic mice supposing that appropriate Cre strains on pure
genetic backgrounds are available that allow the detection of germline transmission by coat color. This would save 3 months required for one breeding step.
(B) The new approach uses hybrid ES cells carrying the Cre gene with an appropriate expression pattern for conditional gene inactivation in mice. Following
the introduction of loxP sites into both alleles of the target gene, the FLP-mediated deletion of the selection marker genes and the injection of these ES cells
into tetraploid blastocysts, conditional mouse mutants are obtained within 6 month. The time required for each step is indicated.
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inactivation, allowing precise gene function analysis in
animals that have undergone normal embryonic development.
The lower degree of deletion observed with the Rosa26 allele
(lacZ reporter) con®rms the position dependency of Cre-
mediated recombination described by Vooijs et al. (11). Since
all other targets tested so far achieved near complete excision
with the rosa(CreERT2) con®guration (Fig. 2 and unpublished
observations), a limited accessibility may be restricted to only
a minority of loxP-¯anked loci. As the rosa(CreERT2) allele
permits inducible gene inactivation in all organs, it should ®nd
broad application as a research tool in reverse mouse genetics.
We have employed the tetraploid blastocyst complementa-
tion approach for in vivo analysis of the rosa(CreERT2)
con®guration, allowing the generation of ES cell-derived mice
(ES mice) in a single step without the requirement of time-
consuming breeding. Tetraploid blastocysts are not capable of
completing normal development, but, when complemented by
the introduction of diploid ES cells, support the development
of solely ES cell-derived mice. The ef®cient generation of
such ES mice using non-transgenic hybrid ES cells has been
recently demonstrated (16). In this study, the authors also
succeeded in generating a single ES mouse through tetraploid
blastocyst complementation using transfected cells that had
undergone two consecutive rounds of selection. However, it
remained unclear whether ES cells maintain their potency to
complement tetraploid embryos with suf®cient ef®ciency and
reproducibility even after additional genetic modi®cations,
which is a prerequisite for the strategy depicted in Figure 5B.
We introduced both the CreERT2 coding region and a lacZ
reporter construct into hybrid ES cells by targeted insertion
into the Rosa26 locus. The targeting strategy involved three
consecutive rounds of transfection and selection with the
antibiotics G418 and hygromycin B. We found that all
targeted ES cell clones produced ES-derived mice with high
ef®ciency. The proportion of transferred blastocysts that
developed into live born pups was in the range 8±17% and did
not signi®cantly decrease using ES cells that had undergone
three consecutive transfections (Fig. 2A). Thus, we demon-
strate that hybrid ES cells can be exposed to at least three
transfection cycles without affecting the potency to comple-
ment tetraploid embryos, allowing the analysis of complex
genetic alterations in ES cell-derived mice within the time of a
single mouse generation.
Our ®ndings provide the proof of principle for a new
concept allowing the rapid production of inducible knockout
mice using tetraploid blastocyst complementation. So far, the
derivation of conditional mouse mutants had been a time-
consuming undertaking since three breeding steps (3 months
each) are usually required to obtain mice combining two
copies of the loxP-¯anked allele and the recombinase
transgene (Fig. 5A). To address this limitation, we propose a
new strategy that involves the tetraploid blastocyst comple-
mentation approach for the one step generation of conditional
mouse mutants from genetically engineered ES cells. The
generation of ES cells from Cre transgenic mice is feasible
using standard protocols (15), as demonstrated by O'Gorman
and colleagues (27). Three transfection cycles are suf®cient to
introduce loxP sites into both alleles of the target gene in ES
cells, following the strategy depicted in Figure 5B. Thus, by
using Cre transgenic ES cell lines for the generation of the
loxP-¯anked alleles, it will be possible to produce conditional
mouse mutants directly from the targeted ES cells through
tetraploid blastocyst complementation. Using this scheme,
adult (2 months old) inducible mouse mutants available for
phenotypic analyses can be obtained within 6 months,
required for three gene targeting steps (1 month each) and
one mouse generation time (3 months) (Fig. 5B). This saves
more than 50% of time as compared to the current conditional
gene targeting protocol, which requires 14 months including
two targeting steps and four mouse generations (Fig. 5A).
Since the described approach is simple and technically not
more demanding than the current knockout protocol, we
expect that this strategy will become a widely used tool in
reverse mouse genetics.
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